Literature DB >> 9358138

A comparison of low-dose inhaled budesonide plus theophylline and high-dose inhaled budesonide for moderate asthma.

D J Evans1, D A Taylor, O Zetterstrom, K F Chung, B J O'Connor, P J Barnes.   

Abstract

BACKGROUND: Inhaled glucosteroids and oral theophylline are widely used to treat asthma. We compared the benefits of adding theophylline to inhaled glucosteroid with those of doubling the dose of inhaled glucosteroid in patients with persistent symptoms despite the use of inhaled glucosteroid.
METHODS: In a double-blind, placebo-controlled trial, we randomly assigned 62 patients to receive either 400 microg of inhaled budesonide (low-dose budesonide) with 250 or 375 mg of theophylline (depending on body weight) or 800 microg of inhaled budesonide (high-dose budesonide). All doses were given twice daily for three months. Lung function was measured serially, and patients kept records of peak expiratory flow, symptoms, and albuterol use. The effects of treatment on endogenous cortisol levels were also assessed.
RESULTS: Both treatments resulted in improvements in lung function that were sustained throughout the study. As compared with treatment with high-dose budesonide, treatment with low-dose budesonide plus theophylline resulted in greater improvements in forced vital capacity (P=0.03) and forced expiratory volume in one second (P= 0.03). There were significant and similar reductions in beta2-agonist use and the variability of peak expiratory flow, a correlate of bronchial hyperresponsiveness and the severity of asthma. Serum cortisol concentrations were significantly reduced in the group given high-dose budesonide (from a mean [+/-SE] of 18.4+/-2.4 microg per deciliter to 15.9+/-2.1 microg per deciliter, P=0.02) but were unchanged in the other group. The median serum theophylline concentration was 8.7 microg per milliliter (therapeutic range, 10 to 20) among those who received theophylline. Both treatments were well tolerated.
CONCLUSIONS: For patients with moderate asthma and persistent symptoms, low-dose inhaled budesonide with theophylline and high-dose inhaled budesonide produced similar benefits. Effects were achieved at theophylline concentrations below the recommended therapeutic range. The addition of low-dose theophylline to inhaled glucosteroid may be preferable to and cheaper than increasing the dose of inhaled glucosteroid.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9358138     DOI: 10.1056/NEJM199711133372002

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  51 in total

Review 1.  Severe acute asthma.

Authors:  S Salmeron; M Bard; F X Blanc; A Ellrodt
Journal:  Clin Rev Allergy Immunol       Date:  1999       Impact factor: 8.667

Review 2.  Outcome measures in asthma.

Authors:  N C Barnes
Journal:  Thorax       Date:  2000-08       Impact factor: 9.139

3.  A molecular mechanism of action of theophylline: Induction of histone deacetylase activity to decrease inflammatory gene expression.

Authors:  Kazuhiro Ito; Sam Lim; Gaetano Caramori; Borja Cosio; K Fan Chung; Ian M Adcock; Peter J Barnes
Journal:  Proc Natl Acad Sci U S A       Date:  2002-06-17       Impact factor: 11.205

Review 4.  Management of asthma in adults: current therapy and future directions.

Authors:  R H Green; C E Brightling; I D Pavord; A J Wardlaw
Journal:  Postgrad Med J       Date:  2003-05       Impact factor: 2.401

Review 5.  Newer drugs for asthma.

Authors:  Meenu Singh
Journal:  Indian J Pediatr       Date:  2004-08       Impact factor: 1.967

Review 6.  Oral xanthines as maintenance treatment for asthma in children.

Authors:  P Seddon; A Bara; F M Ducharme; T J Lasserson
Journal:  Cochrane Database Syst Rev       Date:  2006-01-25

Review 7.  Pharmacotherapy of critical asthma syndrome: current and emerging therapies.

Authors:  T E Albertson; M Schivo; N Gidwani; N J Kenyon; M E Sutter; A L Chan; S Louie
Journal:  Clin Rev Allergy Immunol       Date:  2015-02       Impact factor: 8.667

8.  Comparison of high dose inhaled steroids, low dose inhaled steroids plus low dose theophylline, and low dose inhaled steroids alone in chronic asthma in general practice.

Authors:  S Lim; A Jatakanon; D Gordon; C Macdonald; K F Chung; P J Barnes
Journal:  Thorax       Date:  2000-10       Impact factor: 9.139

Review 9.  Recent changes: pulmonary medicine.

Authors:  N Roche
Journal:  BMJ       Date:  1999-01-16

10.  Can the anti-inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking?

Authors:  M A Giembycz
Journal:  Br J Pharmacol       Date:  2008-07-28       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.